Empagliflozin

Limits on what this shows

• Key negative/null findings: No study located in this review, at any tier, reported empagliflozin increasing mitochondrial damage, reducing mitochondrial density, or impairing mitochondrial biogenesis in any tissue.
• At-risk subgroups: Not established; all evidence is preclinical, so no human subgroup can be identified from the sources reviewed.

Regulatory status

Not addressed in the current US FDA label; the label contains no mitochondrial-function language of any kind.

Population evidence

All empagliflozin-specific mitochondrial studies retrieved in this review are animal or cardiomyocyte models, not human trials: empagliflozin attenuated cardiac microvascular ischemia/reperfusion injury by improving mitochondrial homeostasis in a mouse model (2022, PMID 35705980); empagliflozin improved mitochondrial dysfunction in diabetic cardiomyopathy via ketone-body metabolism in a diabetic mouse model (2024, PMID 38160540); and empagliflozin attenuated myocardial oxidative stress and fibrosis in a diabetic mouse heart (2019, PMID 30710997). All three describe empagliflozin protecting or restoring mitochondrial function under metabolic stress; none describe empagliflozin causing mitochondrial injury or increased burden. No Tier A human study measuring a mitochondrial-function parameter in an empagliflozin cohort was located.

Mechanism

The proposed mechanism in these studies (AMPK-alpha1/ULK1/FUNDC1-mediated mitophagy, ketone-body substrate shift) is empagliflozin's own proposed cardioprotective and renoprotective therapeutic mechanism, the same biology behind the drug's heart-failure and CKD indications. Per this dossier's protocol, a drug's own beneficial mechanism of action is not filed as a nutrient- or organelle-deficiency finding.

Counter-evidence held on record

All three animal studies found here are, in effect, counter-evidence to a "burden" hypothesis: each was designed to test, and reports, a protective mitochondrial effect, not a harmful one. Never present this entry as evidence of mitochondrial harm. It exists to record that the mitochondrial-burden question was checked and that the only evidence found, though preclinical only, runs opposite to a deficiency narrative. No supplement or mitochondrial-support recommendation is implied.

Limits on what this shows

• Key negative/null findings: A dedicated randomized, double-blind, placebo-controlled trial protocol measuring empagliflozin's effect on RNA and DNA oxidation (8-oxoGuo and 8-oxodG) in type 2 diabetes was registered and published as a protocol (2017, PMID 28490557); a subsequent results paper covering two- and twelve-week SGLT2 inhibition and DNA/RNA oxidation was located (2023, PMID 37171199), but this review could not confirm from the retrieved snippet whether empagliflozin specifically, rather than another SGLT2 inhibitor, was the study drug, nor the direction of the reported effect, after repeated access attempts. It is named here for completeness and flagged as unverified; no statistic is drawn from it.
• At-risk subgroups: Not established for empagliflozin specifically in the sources reviewed.

Regulatory status

Not addressed in the current US FDA label; no oxidative-stress-related warning or monitoring requirement is present.

Population evidence

A human study of empagliflozin in heart failure with preserved ejection fraction reported improved endothelial and cardiomyocyte function "via reduced pro-inflammatory-oxidative pathways" (2021, PMID 32396609); this review retrieved the title and this direction-bearing phrase but could not independently confirm the journal or full numeric results, so no effect size is cited from it. Animal studies specific to empagliflozin report the same direction: reduced myocardial oxidative stress and fibrosis in diabetic mice (2019, PMID 30710997) and reduced oxidative stress alongside improved mitochondrial function in diabetic cardiomyopathy models (2024, PMID 38160540).

Mechanism

Proposed mechanisms center on reduced inflammatory and pro-oxidant signaling downstream of improved glycemic control and the ketone-body substrate shift discussed under Mitochondrial burden, again framed in the source literature as part of empagliflozin's therapeutic, not harmful, action.

Counter-evidence held on record

No source located in this review, at any tier, reports empagliflozin increasing oxidative stress markers in humans or animals. Never present this as a deficiency or as a reason to add antioxidant supplementation. Where direction is established at all, it runs toward reduced oxidative stress; where it is not established (the flagged 2023 trial), it is left unresolved rather than assumed in either direction.

Limits on what this shows

• Key negative/null findings: The same trial found CRP, IL-6, and uric acid all declined significantly alongside ferritin, and ferritin correlated positively with both IL-6 (p=0.04) and uric acid (p=0.03) but not with CRP (p=0.22). Because ferritin is itself an acute-phase reactant that rises with inflammation, a falling ferritin alongside falling IL-6 is also consistent with reduced inflammatory ferritin elevation rather than, or in addition to, true iron-store depletion. This trial cannot separate the two explanations.
• At-risk subgroups: Two further empagliflozin-specific titles identified in this review, "Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease" (2020, PMID 31707794) and "Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes" (2021, PMID 34378852), address this same question directly in named empagliflozin cohorts, but their full text could not be independently retrieved in this review beyond the title (see Sources); they are named here as corroborating candidates, not relied on for any statistic. No subgroup analysis by baseline iron status, sex, or renal function was available in the source retrieved.

Regulatory status

Not addressed in the current US FDA label; no iron warning, monitoring requirement, or supplementation guidance is present for empagliflozin.

Population evidence

A quasi-experimental trial at Kerman University of Medical Sciences (2022-2023) gave 44 prediabetic and type 2 diabetic adults, aged 18-65 and not previously on glucose-lowering medication, empagliflozin 10 mg daily for three months. Serum ferritin decreased and TIBC increased significantly (p<0.05) from baseline to endpoint ("Effect of Empagliflozin on Serum Ferritin and Its Relationship With Inflammatory Markers in Prediabetic and Diabetic Patients," Journal of Diabetes Research, 2025, PMID 40151322). This is a pre-post design without a placebo or untreated comparator arm, so it establishes a within-person change temporally associated with empagliflozin, not a controlled effect estimate.

Mechanism

The proposed mechanism is increased erythropoietin-driven erythropoiesis (see Oxygen delivery/utilization, below) mobilizing stored iron for new red-cell production, lowering circulating ferritin as a marker of iron stores while raising TIBC as the body's iron-binding capacity responds to lower stored iron. This is distinct from the renal tubular mechanism proposed for the magnesium and phosphate findings elsewhere in this dossier.

Counter-evidence held on record

The same trial's own correlation data (ferritin tracking with IL-6 and uric acid, not CRP) is the strongest available counter-explanation: some or all of the ferritin fall may reflect resolving inflammation rather than iron mobilization. No study in this review measured hemoglobin or clinical anemia incidence alongside these markers in the same cohort, so this entry describes a laboratory-marker shift, not a documented anemia risk. Do not present this as a diagnosed iron deficiency or as grounds for iron supplementation. The evidence is a single small, uncontrolled, pre-post trial with a plausible non-iron explanation (falling inflammation) for part or all of the ferritin change. If surfaced to consumers, this must be framed as an unresolved laboratory signal worth mentioning to a prescriber if a metabolic panel is already being drawn, not as a deficiency finding.

Limits on what this shows

• Key negative/null findings: None available; absence of a study is not the same as a negative study, and none is claimed here.
• At-risk subgroups: Cannot be determined from an empty evidence base.
• Dose/duration: Not applicable; no dose or duration relationship can be described without any underlying study.

Regulatory status

Not addressed in the current US FDA label; copper is not mentioned anywhere in the label.

Population evidence

A direct search for empagliflozin combined with copper returned two results, neither relevant: one is an unrelated organic-chemistry synthesis paper using "copper-catalyzed" reaction conditions to build an SGLT2-inhibitor-class molecule, and the other is an unrelated diabetic-rat study of quercetin and calcium-channel regulation that mentions serum copper only as an incidental analyte, not in relation to any SGLT2 inhibitor. A broadened search for the SGLT2 inhibitor class together with copper, zinc, or trace-element status returned zero results. Both searches were run September 10, 2026.

Mechanism

No mechanism connecting empagliflozin to copper absorption, excretion, or utilization has been proposed in any source located in this review. None of the mechanism classes screened elsewhere in this dossier (renal tubular handling, absorption interference, cofactor antagonism) have been tested for copper specifically with this drug.

Counter-evidence held on record

A single study, at any tier, directly measuring serum or tissue copper (or a validated functional copper marker such as ceruloplasmin) in patients or animals treated with empagliflozin or another SGLT2 inhibitor, with a comparator arm. Do not present this evidence gap as reassurance that empagliflozin is safe for copper status, and do not present it as a reason for suspicion either. It is genuinely unstudied. No supplement recommendation is implied by an absence of data in either direction.

Limits on what this shows

• Key negative/null findings: None of the empagliflozin-specific titles located frame their findings as harmful or as a deficiency-adjacent risk; the framing found is uniformly associative or favorable. No empagliflozin-specific study reporting dysbiosis, reduced microbial diversity, or an adverse gut-health outcome was located in this review.
• At-risk subgroups: This dossier's population confounder already on record applies directly here: type 2 diabetes itself is independently associated with altered gut microbiota, and metformin, frequently co-prescribed with empagliflozin, has its own well-documented, separate effect on gut microbial composition. None of the empagliflozin-specific titles located in this review report having isolated an empagliflozin-only effect from these two confounders with a metformin-controlled or drug-naive comparator arm; this review could not confirm their designs did so, so confounding by indication and by co-therapy is presumed unresolved rather than ruled out, per this dossier's standing protocol.

Regulatory status

Not addressed in the current US FDA label; no gut flora or microbiome-related warning is present.

Population evidence

Two empagliflozin-specific human titles were located: "Novel Associations of Empagliflozin on the Gut Microbiome and Metabolome in Type 2 Diabetes" (2022, PMID 35674101) and "Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes" (2022, PMID 35397165); a third, "Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction" (the EMPAGUM trial, 2023, PMID 37223722), is a published trial design/protocol paper, not a results paper. This review could not independently retrieve full text or numeric results for any of the three beyond their titles, which describe empagliflozin's microbiome effects as "associations" and "cardiovascular benefits," not as adverse dysbiosis; no statistic is drawn from them here. A class-level review, "Pharmacological modulation of the diabetic gut microbiome with gliflozin drugs" (2025, PMID 40979553), was also located but is not stratified to empagliflozin alone and is treated as Tier C context only.

Mechanism

Any genuine empagliflozin-specific mechanism would most plausibly run through increased urinary glucose loss altering colonic substrate availability, or through the drug's metabolic effects on the host altering microbial selection pressure indirectly. None of the retrieved titles specify a mechanism beyond "association."

Counter-evidence held on record

The titles retrieved lean toward favorable or neutral framing ("cardiovascular benefits... associated with," "novel associations"), which is itself evidence against a harm narrative, though this review could not verify the underlying data behind those titles. Do not present this as an established microbiome risk. The honest state of the evidence is that empagliflozin-specific human data exist, appear directionally favorable where framed at all, and have not been shown in this review to survive separation from diabetes- and metformin-driven microbiome change. No probiotic or microbiome-support recommendation is implied.

Limits on what this shows

• Key negative/null findings: No source located in this review reports empagliflozin lowering hematocrit, hemoglobin, or another oxygen-carriage parameter.
• At-risk subgroups: Not established as a risk subgroup in the sources reviewed; the label frames the hematocrit rise as a laboratory finding among treated patients generally, not as a flagged risk to any named subgroup.

Regulatory status

Addressed directly in Section 6.1 (Clinical Trials Experience) of the current US FDA label: "In a pool of four placebo-controlled studies, median hematocrit decreased by 1.3% in placebo and increased by 2.8% in JARDIANCE 10 mg and 2.8% in JARDIANCE 25 mg treated patients," and hematocrit elevations above the reference range occurred in 2.7-3.5% of empagliflozin-treated patients versus 0.6% on placebo.

Population evidence

The label figure is drawn from a pool of four placebo-controlled trials with empagliflozin directly in the cohort, Tier A. This is consistent with the class-wide, and empagliflozin-specific, literature on SGLT2 inhibitors increasing erythropoietin and stimulating erythropoiesis; a title-level candidate located in this review, "Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease" (2020, PMID 31707794), addresses this question directly in an empagliflozin cohort, but its full text could not be independently retrieved in this review beyond the title, so no statistic is drawn from it.

Mechanism

Two mechanisms are proposed in the literature and are not mutually exclusive: plasma-volume contraction from osmotic diuresis concentrating existing red cells (hemoconcentration), and genuine stimulation of erythropoietin and erythropoiesis independent of volume status. The label data alone cannot distinguish between the two; see Overlap map for how this entry relates to the existing volume-depletion finding elsewhere in this dossier.

Counter-evidence held on record

None located; every source found in this review, at every tier, agrees on the direction (increase, not decrease). Never present this as anemia risk or as grounds for iron or oxygen-support supplementation. The documented direction is an increase in a marker of oxygen-carrying capacity, not a deficiency. Whether the mechanism is partly hemoconcentration from volume contraction (see the label's own volume-depletion warning, cited elsewhere in this dossier) or genuine erythropoiesis is not fully resolved by the sources reviewed and is not needed to state the direction correctly.

Limits on what this shows

• Key negative/null findings: This entire entry is a key negative finding: a direct, validated, drug-specific measurement of ATP-related cardiac energetics found no significant change in either direction, in two separate heart-failure populations, at rest and under stress.
• At-risk subgroups: None identified; the null result held across both HFrEF and HFpEF subgroups tested.

Regulatory status

Not addressed in the current US FDA label; no ATP or cellular-energy-related warning is present.

Population evidence

The EMPA-VISION trial ("Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin," 2023, PMID 37070436) randomized patients with heart failure with reduced and with preserved ejection fraction to empagliflozin or placebo and measured the myocardial phosphocreatine-to-ATP ratio (PCr/ATP) directly by 31-phosphorus magnetic resonance spectroscopy, both at rest and under dobutamine stress, after 12 weeks. The trial reported: "Empagliflozin treatment did not change cardiac energetics (i.e., PCr/ATP) at rest in HFrEF...or HFpEF...Likewise, there were no changes in PCr/ATP during dobutamine stress." This is Tier A, empagliflozin directly in the cohort, the parameter directly measured by a validated method, with a null result.

Mechanism

No mechanism for ATP depletion is proposed anywhere in the sources reviewed. The trial's own authors concluded, as quoted in the retrieved abstract, that "it is unlikely that enhancing cardiac energy metabolism mediates the beneficial effects of SGLT2i in HF," meaning the trial also rebuts the separate, opposite claim that empagliflozin's cardiac benefit works by boosting ATP production.

Counter-evidence held on record

This entry is itself the counter-evidence to any ATP-depletion or ATP-boost claim for empagliflozin; no contradicting source was located. This is graded yellow as a tested-and-null context flag, not as an unresolved theoretical concern. Do not present it as evidence of harm, and do not present it as evidence that empagliflozin boosts cellular energy either; the trial found neither. No supplement or energy-support recommendation is implied.